gsk-1004723
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00694993)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
Histamine H3 receptor antagonist
- Histamine H1 receptorANTAGONIST
Histamine H1 receptor antagonist
- Histamine H3 receptorINHIBITOR
HRH3 inhibitor
- Histamine H1 receptorINHIBITOR
HRH1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1- Mol. weight
- 641.3 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1767164 ↗
Also known as
- gsk1004723
- gsk1004723
- gsk1004723
- gsk 1004723
- gsk-1004723
- gsk-1004723
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00972504 | Phase 2 | Jun 1, 2009 | GlaxoSmithKline |
| NCT00824356 | Phase 2 | Jun 1, 2008 | GlaxoSmithKline |
| NCT00694993 | Phase 1 | Dec 1, 2007 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2007 |
1 organizations
Page 1 / 1